Prominent TG2 expression has been identified in a diverse range of cancers including leukaemia, prostate cancer, breast cancer, renal cancer, lung cancer, ovarian cancer, glioblastoma, cervical cancer, colorectal cancer, squamous cell cancers, mesothelioma, and pancreatic cancer [8,9,10,11,12,13,14,15,16,17,18]. Here, TGM2 is linked to ovarian carcinoma.